Ascendis Pharma Growth Disorders A/S: Financial statements 2017
CVR: 32323677
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2017. In 2017, the company reported a gross profit of EUR -13,183,449 and a net result of EUR -13,676,348 compared with EUR -6,149,421 the year before. Equity in the 2017 report amounted to EUR -23,019,792.
- Gross Profit
- EUR -13,183,449
- Profit/Loss
- EUR -13,676,348
- Equity
- EUR -23,019,792
- Total Assets
- EUR 2,111,343
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | -13.2M EUR | -13.7M EUR | -23M EUR | 0 |
| 2016 | - | -5.9M EUR | -6.1M EUR | -9.3M EUR | - |
| 2015 | - | -2.5M EUR | -2.6M EUR | -3.2M EUR | - |
| 2014 | - | -507K EUR | -603K EUR | -553K EUR | - |
| 2013 | - | -23K | -33K | 89K | - |
Official annual report
Keep an eye on Ascendis Pharma Growth Disorders A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
Ascendis Pharma Growth Disorders A/S has published its annual report for 2016. Gross profit came to DKK -5,944,352, and the net result was DKK -6,149,421.
About Ascendis Pharma Growth Disorders A/S
Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.